Safety Pharmacology Society
8th Annual Meeting Program
Madison, Wisconsin U.S.A.
September 22-25, 2008

Tuesday, September 23

8:15 AM

Welcome and Announcements
Dr. Ian MacKenzie, President of the Safety Pharmacology Society

8:30 AM

President's Keynote Address
Dr. Craig January, University of Wisconsin
Discovery of hERG: Historical Perspectives and Contemporary Concerns

9:30 AM

Break

10:00 AM

A. Translational: Biomarkers (Session Chair Mike Engwall)

ECG and Blood Pressure as biomarkers - orthostatic hypotension
Speaker: Dr. Nancy Poy, Pfizer

Ultrasound as a biomarker of cardiovascular function: valves, hypertrophy, and vascular
Serum Chemistry Parameters as Cardiovascular Biomarkers  
Speaker: To be confirmed

B. Emerging Technologies (Session Co-Chairs, Anthony Bahinski/Craig January)

Stem Cells Session Overview:  
The field of stem cell research has been rapidly accelerating in the last several years. The development of validated human cell-based in vitro safety screens has the potential to facilitate earlier attrition of compounds with unacceptable safety profiles. This session will focus on recent efforts to develop a new source of pluripotent stem cells from somatic tissue and on the development of in vitro models using stem cell derived human tissue for drug safety evaluation.

Stem cells: Emerging Applications in Medicine  
Speaker: To be confirmed

Stem cells: New Developments in Reprogramming  
Speaker: To be confirmed

Stem cells Panel Discussion

C. Integrated Systems Physiology (Session Co-Chairs: Maxim Soloviev, Franz Hock)

Introduction to Chronobiology  
Speaker: Prof. Dr. med. Dr. h.c. Björn Lemmer Institut für Experimentelle & Klinische Pharmakologie & Toxikologie

Chronopharmacology: Considerations for Drug Development  
Speaker: Prof. Dr. med. Dr. h.c. Björn Lemmer Institut für Experimentelle & Klinische Pharmakologie & Toxikologie

Overview of Sleep Apnea  
Speaker: Dr. Gordon Mitchell, University of Wisconsin

Cardiopulmonary Complications of Apnea
12:00 PM

**LUNCH Break (Exhibits Hall)**

**Poster Viewing**

A total of 16 Oral Presenters (open to junior and senior scientists) will be selected based on the merit of their abstracts submitted for presentation at the 2008 Safety Pharmacology Society meeting in Madison, Wisconsin USA. The abstracts selected will reflect a diversity of topics including emerging trends. Each presenter will have time for a 12 minute presentation with 3 minute question session. In addition, each presenter will have a poster viewing during the meeting.

12:00 PM

**A. Invited Oral Communications 1**

2:00 PM 1. Presentation selected from submitted abstracts
2:15 PM 2. Presentation selected from submitted abstracts
2:30 PM 3. Presentation selected from submitted abstracts
2:45 PM 4. Presentation selected from submitted abstracts

**B. Invited Oral Communications 2**

2:00 PM 1. Presentation selected from submitted abstracts
2:15 PM 2. Presentation selected from submitted abstracts
2:30 PM 3. Presentation selected from submitted abstracts
2:45 PM 4. Presentation selected from submitted abstracts

3:00 PM

**Break**

3:30 PM

**A. Translational** (Session Chair, Ian MacKenzie)
EEG and relevance in evaluation of sleep and seizure  
Speaker: [Invited] Dr. Joseph Arezzo, Albert Einstein College of Medicine, New York

Gastrointestinal System: Importance of early screening for ulcer, gastric secretion, and emesis  
Speaker: To be confirmed

Regulatory and clinical perspective on biomarkers: How much value do they really provide?  
Speaker: To be confirmed

B. Emerging Technologies (Session Chair, Anthony Bahinski)

Session Overview:  
With increasing emphasis on mechanistic studies, the emergence of biotherapeutics and earlier involvement in the drug discovery process, there is an increasing need for novel in vivo models beyond the core battery of safety pharmacology assays. This session will focus on recent efforts to develop a new generation of mice with completely humanized immune systems to evaluate the safety of biologics and the use of RNAi and transgenic animals to provide early insights into target safety.

Novel in-vivo models—Humanized/Transgenic models  
Speaker: To be confirmed

Novel in-vivo models—RNAi/ssRNA/naked  
Speaker: To be confirmed

DNA therapies, challenges and working methods of administration  
Speaker: To be confirmed

C. Integrated Systems Physiology (Session Chair, Ted Baird)

Neural Regulation of the Gastrointestinal Tract  
Speaker: Dr. Gary M. Mawe, University of Vermont

Mechanisms of Visceral/Cardiac Pain Perception  
Speaker: Dr. Robert D. Foreman, Department of Physiology, University of Oklahoma Health Sciences Center
5:00 PM

Adjourn Day 1

Wednesday, September 24

8:00 AM

A. Translation: Issues in Personalized Medicine (Session Chair, Dusty Sarazan)

A Personal Experience in the Treatment of Depression
Speaker: To be confirmed

The Science Behind the Story: Individual considerations in treatment
Speaker: To be confirmed

Aging Populations- From Pediatric to Geriatric: Not Just Healthy Volunteers.
Speaker: To be confirmed

B. Emerging Strategies (Session Co-Chairs, Alan Bass/Neils-Christian Ganderup)

Introduction
Speaker: Alan Bass, Schering Plough, Kenilworth, N.J.

Beyond hERG
Speaker: To be confirmed

Beyond QT prolongation
Speaker: To be confirmed

Industry Consortia: An update
Speaker: Neils-Christian Ganderup, Ellegaard Göttingen Minipigs A/S

C. Integrated Systems Physiology (Session Chair, Scott Mittelstadt)
Thrombosis
Speaker: Dr. John Folts, Professor of Medicine, Director, Coronary Thrombosis Research and Prevention Laboratory, University of Wisconsin.

Baroreflex in Blood Pressure Regulation
Speaker: Jeanne Seagard, PhD, Department of Anesthesiology, Zablocki Department of Veterans Affairs Medical Center, Medical College of Wisconsin

9:30 AM
Break

10:00 AM

A. Translational (Session Chair, Dusty Sarazan)

Population Differences- How Does Gender and Race Influence Personalized Medicine?
Speaker: Dr. Jon Ruckle, Medical Director Covance, Honolulu, HI

B. Emerging Strategies (Session Chair, Alan Bass)

Discovery Drug Safety Studies: Select the best candidate to develop
Speaker: To be confirmed

Frontloading Safety Pharmacodynamic Testing: Discovery phase exploratory drug safety
Speaker: To be confirmed

C. Integrated Systems Physiology (Session Chair, Dennis Murphy)

Ventilatory Control: Carotid Body Plasticity and Pharmacology
Speaker: Gerald Bisgard, Professor Emeritus Comparative Biosciences, University of Wisconsin
Effects of Gender and Age on Ventilatory Control
Speaker: Mary Behan, Professor of Comparative Biosciences, Veterinary Medical School, University of Wisconsin

11:00 AM

Safety Pharmacology Society Annual Meeting & Awards

12:30 PM

LUNCH Break

A total of 16 Oral Presenters (open to junior and senior scientists) will be selected based on the merit of their abstracts submitted for presentation at the 2008 Safety Pharmacology Society meeting in Madison, Wisconsin USA. The abstracts selected will reflect a diversity of topics including emerging trends. Each presenter will have time for a 12 minute presentation with 3 minute question session. In addition, each presenter will have a poster viewing during the meeting.

2:00 PM

A. Invited Oral Communications 3

2:00 PM 1. Presentation selected from submitted abstracts
2:15 PM 2. Presentation selected from submitted abstracts
2:30 PM 3. Presentation selected from submitted abstracts
2:45 PM 4. Presentation selected from submitted abstracts

B. Invited Oral Communications 4

2:00 PM 1. Presentation selected from submitted abstracts
2:15 PM 2. Presentation selected from submitted abstracts
2:30 PM 3. Presentation selected from submitted abstracts
2:45 PM 4. Presentation selected from submitted abstracts
3:00 PM

**Break**

---

3:30 PM

**A. Translation Track** (Session Chair, Kristy Bruse)

*Predictivity Model/Frame—What are the Tools and How are They Used for Predicting Liability?*
Speaker: Dr. Rob Wallis, Pfizer

*Case Study—Applying Biomarker tools to predict abuse liability*
Speaker: To be confirmed

*Panel Discussion—Personalized Medicine*
Speakers: To be confirmed

**B. Emerging Strategies—Integration of Toxicity and Safety Pharmacology Studies in Risk Assessment** (Session Chair, Sharon Rowton/Alfred Botchway)

*Single vs. multi dose studies*
Speaker: Dr. Wil Redfern

*Case studies to answer why you would/or not consider cross discipline assessment*
Speaker: To be determined

*CV, CNS, Respiratory: How to use established models for combined risk assessment*
Speaker: Mary-Jeanne Kallman, Eli Lilly

**C. Integrated Systems Physiology** (Session Chair, Ted Baird)

*Ophthalmology and the Physiology of the Eye*
Speaker: To be confirmed

*Long-Term Regulation of Blood Pressure: Endocrine and Renal*
Speaker: Dr. Kim Hoagland, Merck & Co., Inc., West Point, Pennsylvania, USA.

**Drug-Induced Activation of Immune Function: Mechanisms and Potential Adverse Effects**
Speaker: Curtis Maier, Director of Immunotoxicology, GlaxoSmithKline Pharmaceuticals

5:00 PM

Adjourn Day 2

**Thursday, September 25**

8:15 AM

**Introduction to Biologics** (Session Chair, Tom Beck)
Speaker: Hugo Vargas, Amgen, Thousand Oaks, CA

This presentation will give an overview of the commonly encountered biologic molecules and touch on potential complexities these types of molecules present for safety pharmacology.

8:45 PM

**Point-Counter Point: Integration of Safety Pharmacology Endpoints in Toxicology Studies for Biologics Testing**
(Session Chair, Tom Beck)
Speakers: To be confirmed

This discussion will present the advantages and disadvantages of incorporation of Safety Pharmacology endpoints into/toxicology studies conducted with large molecules. Each speaker will present his or her view and critically evaluate the others views.
9:30 AM

Break

10:00 AM

**Biologics and Safety Pharmacology: A regulatory perspective**
(Session Chair, Alan Bass)
Speaker: [Invited] Scientist from US FDA

11:00 AM

**Biologics and Safety Pharmacology: A clinical perspective**
(Session Chair, Alan Bass)
Speaker: Dr. Steve Flach, Medical Director, Covance Madison.

11:45 AM

**Closing Remarks**

12:00 PM

**Annual Meeting Adjourns**